Home » Stocks » CORT

Corcept Therapeutics Incorporated (CORT)

Stock Price: $28.14 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 3.27B
Revenue (ttm) 356.03M
Net Income (ttm) 109.40M
Shares Out 115.73M
EPS (ttm) 0.89
PE Ratio 31.62
Forward PE 38.02
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $28.14
Previous Close $28.14
Change ($) 0.00
Change (%) 0.00%
Day's Open 27.62
Day's Range 27.48 - 28.36
Day's Volume 608,130
52-Week Range 10.11 - 28.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Investors Business Daily - 1 month ago

On Friday, Corcept Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Corcept Therapeutics Sees Its Composite Rating Rise To 96 appeared first on Inve...

Zacks Investment Research - 1 month ago

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat se...

InvestorPlace - 1 month ago

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is ...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat se...

Seeking Alpha - 2 months ago

Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year.

Seeking Alpha - 2 months ago

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate up...

The Motley Fool - 3 months ago

A patent decision on its cortisol therapy Korlym is expected to be rendered next month.

GuruFocus - 4 months ago

Growth-focused investors may be interested in the following stocks since their price-earnings ratios still trade below 20 and their trailing 12-month earnings per share have grown significantl...

Other stocks mentioned: LL, PDEX
Zacks Investment Research - 4 months ago

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well.

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat...

Zacks Investment Research - 4 months ago

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

GuruFocus - 4 months ago

The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.

Other stocks mentioned: ATNX, CAL, DXC, TWTR
Business Wire - 5 months ago

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Seeking Alpha - 5 months ago

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...

GlobeNewsWire - 5 months ago

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate...

GlobeNewsWire - 5 months ago

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...

GlobeNewsWire - 5 months ago

MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...

Investors Business Daily - 6 months ago

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Other stocks mentioned: QDEL, VEEV, VRTX
Investors Business Daily - 6 months ago

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared fir...

Other stocks mentioned: ALXN, VRTX
Zacks Investment Research - 6 months ago

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

GlobeNewsWire - 6 months ago

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...

GlobeNewsWire - 7 months ago

MENLO PARK, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...

InvestorPlace - 7 months ago

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: DVAX, GTHX, IMGN, KDMN, SUPN, VRTX
Zacks Investment Research - 7 months ago

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 7 months ago

Is (CORT) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 8 months ago

MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat s...

The Motley Fool - 8 months ago

This biotech company has seen huge growth over the past five years.

Investors Business Daily - 8 months ago

Corcept Therapeutics sees its Relative Strength Rating move into the 80-plus level. The post Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating appeared first on Inv...

Zacks Investment Research - 8 months ago

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

Seeking Alpha - 8 months ago

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 9 months ago

Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.

Other stocks mentioned: FLWS, IUSG, KGC, MGK, NPTN, SCHG, SPYG, TREE, VUG
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.

Zacks Investment Research - 9 months ago

Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that tre...

Zacks Investment Research - 9 months ago

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 10 months ago

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat...

Zacks Investment Research - 10 months ago

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

Seeking Alpha - 10 months ago

Corcept Therapeutics, Inc. (CORT) CEO Joseph Belanoff on Q4 2019 Results - Earnings Call Transcript

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clin... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Joseph Belanoff
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
CORT
Full Company Profile

Financial Performance

In 2019, CORT's revenue was $306.49 million, an increase of 21.99% compared to the previous year's $251.25 million. Earnings were $94.18 million, an increase of 24.89%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 25.75, which is a decrease of -8.49% from the latest price.

Price Target
$25.75
(-8.49% downside)
Analyst Consensus: Buy